This week, Sarepta's JOURNEY natural history study opened in Italy and the UK. It is currently only active in the US, but will in the future involve 30 clinical centres on various continents. The study involves patients with LGMDR3-2D, R4-2E, R5-2C. GFB held a webinar on Saturday February 12th 2022, where Prof. Yvan Torrente explained the JOURNEY study and how to participate in the project. The webinar was held in English and Italian.
Click HERE to watch the WEBINAR
